Adding to the pressure is that CVS Health has retained coverage of Zepbound's arch rival Wegovy (semaglutide), sold by Novo ...

Bloomberg journalists discuss today's biggest winners and losers in the stock market. Listen for analysis on the companies ...

The results were the company's first since its March capital markets day, when it said it would grow top-line production and increase shareholder returns over the next five years. Cigna Group swung to ...

Novo Nordisk shares rose by more than 5% after the Danish weight-loss drug maker said the Food and Drug Administration accepted a new drug application for a pill form of its popular Wegovy injection.

Misperceptions and a focus on weight-loss medications risk oversimplifying a complex health crisis. Read more at straitstimes ...